Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...

Taking a GLP-1 receptor agonist was associated with a lower risk for cirrhosis and related complications in patients with ...

People with type 2 diabetes who use semaglutide drugs like Ozempic and Wegovy appear to have a lower risk of Alzheimer's ...

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of ...

In a pooled analysis of clinical trial data on diabetic patients at high cardiovascular risk or with chronic kidney disease, canagliflozin demonstrated consistent benefits across the spectrum of age ...

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.

Semaglutide (Ozempic) was tied to a reduced risk of Alzheimer's disease diagnoses in people with type 2 diabetes, ...

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

The brain has GLP -1 receptors in abundance and, though very little drug seems to be able to cross the blood-brain barrier ...

Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42 ...